| http://www.w3.org/ns/prov#value | - Chilworth, UK - 2 November 2010 - Karus Therapeutics Ltd, a company engaged in the discovery and development of de novo designed molecular-targeted small molecule drugs to treat inflammation and cancer, has commenced preclinical development of its HDAC6 and PI3-Kinase inhibitor programmes for the treatment of immune and inflammatory diseases such as rheumatoid arthritis (RA).
|
